

Maastricht University (UNIMAAS)

The aim of the School for Public Health and Primary Care: Caphri is: High-quality research and teaching focused on health care innovation, ranging from prevention to rehabilitation, from a patient, professional and societal perspective, leading to improvement of health and well-being of the population. Research and teaching are devoted to contribute to improvements in the area of public health and primary care. The School focuses on interventions in the chain of care, starting with prevention and primary care, and ending with aftercare and rehabilitation. The aim of the research is to get insight into the effectiveness of interventions, and their adequacy in meeting prospective patients' needs. Specific attention is paid to the implementation of such evidence based interventions. Interventions are also evaluated from an economic perspective (Health Technology Assessment) and a normative perspective (e.g. consequences for professional and patient roles and responsibilities).

Key Staff

Annelies Boonen's affiliations and titles after graduation as rheumatologist: September 1, 1994 Appointment as Rheumatologist, MD, Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, The Netherlands. December 18, 2002 Assistant professor of Rheumatology, MD, PhD, Department of Internal Medicine, Division of Rheumatology, Univ. Hospital Maastricht, The Netherlands. April 2007 Part-time researcher Caphri research Institute University Maastricht. Thesis University Maastricht, December 18, 2002: Socioeconomic consequences of ankylosing spondylitis. Memberships Editorial Boards: Member Editorial Board Clinical Rheumatology since 2003. Selected publications in the field of outcome in rheumatology: Boers M, Verhoeven A, Markusse M, Van de Laar M, Westhovens R, Van Denderen J, Van Zeven S, Dijkmans B, Peeters A, Jacobs P, Van den Brink H, Schouten H, Boonen A, van der Heijde D, van der Linden SJ. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine alone in early rheumatoid arthritis. *The Lancet* 1997; 350: 309-18. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Molken M, Guillemin F, Dougados M, Mielants H, de Vlam K, van der Tempel H, van der Linden SJ. Work-status and productivity costs due to Ankylosing Spondylitis: comparison among three European countries. *Ann of Rheum Dis* 2002;62:429-37. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Molken M, Guillemin F, Dougados M, Mielants H, de Vlam K, van der Tempel H, van der Linden Sj. Direct costs of ankylosing spondylitis and its determinants. A comparison among three European. *Ann Rheum Dis* 2003;62:732-40. Dadoniene J, Stropuviene S, Venalis A, Boonen A. High work disability among rheumatoid arthritis patients in Lithuania. *Arthritis Rheum (Arthritis Care and Research)*:2004:51(3);433-9.

Contacts

Maastricht University
School for Public Health and Primary Care: Caphri
Minderbroedersweg 4-6
6200 MD Maastricht
Netherlands
Tel: +31 433 88 42 33
Email Boonen: a.boonen@mumc.nl
Web: <http://www.maastrichtuniversity.nl>